目的 探討參烏益腎片聯(lián)合復(fù)方α酮酸片治療慢性腎衰竭的臨床療效。方法 選取2020年4月-2021年3月在商丘市第一人民醫(yī)院就診的90例慢性腎衰竭患者,按隨機(jī)數(shù)字表法分為對(duì)照組和治療組,每組各45例。對(duì)照組口服復(fù)方α酮酸片,4片/次,3次/d。治療組在對(duì)照組基礎(chǔ)上口服參烏益腎片,4片/次,3次/d。兩組連續(xù)治療6個(gè)月。觀察兩組臨床療效,比較兩組腎功能和血清炎癥因子水平。結(jié)果 治療后,治療組的總有效率為95.56%,明顯高于對(duì)照組的總有效率80.00%,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組的胱抑素C(Cys-C)、β₂-微球蛋白(β₂-MG)低于治療前,腎小球?yàn)V過率(eGFR)高于治療前(P<0.05);治療組的Cys-C、β₂-MG低于對(duì)照組,eGFR高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組的血清基質(zhì)金屬蛋白酶-9(MMP-9)、單核細(xì)胞趨化蛋白-1(MCP-1)、中性粒細(xì)胞相關(guān)載脂蛋白(NGAL)水平低于治療前(P<0.05),且治療組的血清MMP-9、MCP-1、NGAL水平明顯低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 參烏益腎片聯(lián)合復(fù)方α酮酸片治療慢性腎衰竭的療效確切,可改善腎功能,降低腎臟炎癥水平,安全性良好。

Objective To investigate the clinical effect of Shenwu Yishen Tablets combined with Compound α-Ketoacid Tablets in treatment of chronic renal failure. Methods Patients (90 cases) with chronic renal failure in Shangqiu First People’s Hospital from April 2020 to March 2021 were divided into control and treatment groups according to random number table method, and each group had 45 cases. Patients in the control group were po administered with Compound α-Ketoacid Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Shenwu Yishen Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and the renal function and the inflammatory factor in two groups were compared. Results After treatment, the total effective rate in the treatment group was 95.56%, which was significantly higher than that in the control group (80.00%), with statistically significant difference (P＜0.05). After treatment, the levels of Cys-C and β₂-MG of two groups were decreased, but the levels of eGFR of two groups were increased (P＜0.05).The levels of Cys-C and β₂-MG in the treatment group were lower than those in the control group, but the levels of eGFR in the treatment group were higher than those in the control group, with a statistically significant difference (P＜0.05). After treatment, the serum levels of MMP-9, MCP-1, and NGAL in two groups were lower than those before treatment (P＜0.05), and the serum levels of MMP-9, MCP-1, and NGAL in the treatment group were significantly lower than those in the control group (P＜0.05). Conclusion Shenwu Yishen Tablets combined with Compound α-Ketoacid Tablets has clinical curative effect in treatment of chronic renal failure, can improve renal function, reduce renal inflammation, with good safety.

R986

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目(LHGJ20191505)